SPECIAL UPDATE: The epidemiology of Breast Implant Associated Large Cell Lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants

Background: The epidemiology and implant specific risk for BIA-ALCL has been previously reported for Australia and New Zealand. We now present updated data and risk assessment since our last report. Methods: New cases in Australia and New Zealand were identified and analyzed. Updated sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) were secured to estimate implant-specific risk. Results: A total of 26 new cases of ALCL were diagnosed between January 2017 to April 2018 increasing the total number of confirmed cases in Australia and New Zealand to 81. This represents a 47% increase in number of reported cases over this time period. The mean age and time to development remains unchanged. The implant specific risk has increased for Silimed Polyurethane (23.4 times higher) as compared with Biocell, which has remained relatively static (16.5 times higher) compared with Siltex implants. Conclusions: The number of confirmed cases of BIA-ALCL in Australia and New Zealand continues to rise. The implant specific risk has now changed to reflect a strong link to implant surface area/roughness as a major association with this cancer. FD - Professor Deva is a consultant, educator and research coordinator for Mentor (J&J), Allergan, Motiva, Sientra and Acelity A/Professor Magnusson is a consultant and educator for Mentor (J&J) and Allergan All correspondence to: Professor Anand Deva , Head, Plastic & Reconstructive Surgery and Co-Director, Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Suite 301, 2 Technology Place, Macquarie University, Sydney, Australia. Email: Anand.deva@mq.edu.au ©2019American Society of Plastic Surgeons

from A via a.sfakia on Inoreader https://ift.tt/2Vb0RPv